Peginterferon alfa-2a biosimilar (Biogenomics)

聚乙二醇化干扰素α2a生物类似药 (Biogenomics)

Report date: 2022/01/14 13:23:58

Base Information

Drug NamePeginterferon alfa-2a biosimilar (Biogenomics)

Drug Alias Name聚乙二醇化干扰素α2a生物仿制药 (Biogenomics)

ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar

Mechanisms of ActionInterferon alpha/beta receptor agonists

TargetsInterferon alpha/beta receptor

Therapy Area/IndicationsHepatitis C

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Clinical)

Highest Status in ChinaN/A

Originator CompaniesBiogenomics

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesBiogenomics

Active IndicationsN/A

Inactive IndicationsHepatitis C

ATC CodeL03AB11